Physician profile
Brian Goodman
NPI 1588293195
$2,777.84
in general payments reported to CMS, 2019-2025
12 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $401 · 2024: $1,126 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,777.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $533.21 | 2023-2025 | Pillcam, Gi Genius, Endoflip |
| Abbvie INC. | $513.02 | 2024-2025 | |
| Janssen Biotech, INC. | $354.75 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $249.60 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $248.22 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $211.69 | 2024-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $165.14 | 2023-2025 | Gattex, Entyvio |
| E.R. Squibb & Sons, L.L.C. | $130.23 | 2023 | Zeposia |
| Gilead Sciences, INC. | $121.84 | 2024 | Livdelzi |
| Alnylam Pharmaceuticals INC. | $119.70 | 2025 | Givlaari |
| Madrigal Pharmaceuticals | $112.57 | 2025 | Rezdiffra |
| Pulmonx Corporation | $17.87 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.